Type 1 Diabetes clinical guidelines: international endocrinology guidance adapted to local market access realities
International guidelines do not speak the language of local payers
A leading endocrinology brand held rights to an advanced insulin delivery system for Type 1 Diabetes. The global medical team had produced a comprehensive clinical guidelines summary based on the latest international standards — ADA, EASD, and ISPAD recommendations.
The problem was translation. Not linguistic translation, but contextual translation. Each priority market had its own reimbursement criteria for T1D technologies: different definitions of 'inadequately controlled diabetes', different thresholds for device eligibility, different comparator technologies currently reimbursed.
Market Access teams in each country were using the international guidelines document as a scientific reference — but they found it difficult to directly deploy in payer meetings because the framing did not match their local HTA body's terminology or decision criteria.
International clinical guidelines are built for global scientific consensus, not for local reimbursement committees. The gap between the two is where access decisions are won or lost.
What we did
Measurable impact
All priority markets received adapted clinical reference documents aligned to their specific access environment. Market Access teams adopted the adapted guidelines as their primary internal reference tool, replacing the generic international document. Several markets subsequently used the adapted framework as a supporting annex in HTA submissions, with all receiving favourable assessments.
clinical references
internal reference
Tell us what you’re working on — we’ll show you relevant cases and suggest the fastest path forward.
From the field:
evidence & practice
AI-powered.
Expert-validated.
We built AI workflows into our daily practice — not as a marketing claim, but as the infrastructure that lets our medical experts deliver faster without cutting corners.